We invite you to participate in a multicenter observational study entitled:
"A prospective, non-interventional observational study of patients with inflammatory bowel disease (IBD) receiving vedolizumab subcutaneously or intravenously to observe the choice of administration route and treatment outcomes (VARIETY)"
To begin the study, it is necessary to sign an online agreement, so please register and follow the instructions that appear on the computer screen.
Please complete the registration form
and join the study